Value of Cabergoline & Low Dose Aspirin in Poor Responders Undergoing

Status Not yet recruiting

Clinical Trial Summary

Ovarian stimulation will be done using the Microdose flare-up regimen. The patient will receive diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation will be initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) will be injected when at least 2 follicles 18 mm were observed on ultrasonography.

Oocytes willbe retrieved 36 hours after hCG injection using a 17-gauge aspiration needle under transvaginal ultrasound guidance. The pelvis is evaluated with ultrasound to ensure that there is no internal bleeding.

After fertilization was confirmed when two polar bodies and two pronuclear were observed 18-20 hours after insemination, one to three grade A embryos were transferred at day 3 fertilization.

The luteal phase support will be initiated from the day of oocyte retrieval for all patients with (Cyclogest 400 mg, Actavis pharmaceutical, UK) vaginal suppositories per day till the day of serum pregnancy test was done.

Clinical Trial Description

Ovarian stimulation was done using the Microdose flare-up regimen. The patient received diluted doses of the GnRH agonist leuprolide acetate 40 µg, given subcutaneously twice daily. Two days later, stimulation is initiated by intramuscular (IM) injections of HMG (Merional, IBSA, Germany) in a dose of 300 IU/day.

Follicular monitoring began from the ninth day of the cycle by serial vaginal ultrasonography and measurement of serum E2 levels. IM injections of 10000 IU HCG (Choriomon; IBSA, Germany) were injected when at least 2 follicles 18 mm were observed on ultrasonography.

Oocytes were retrieved 36 hours after hCG injection using a 17-gauge aspiration needle under transvaginal ultrasound guidance. The pelvis is evaluated with ultrasound to ensure that there is no internal bleeding.

After fertilization was confirmed when two polar bodies and two pronuclear were observed 18-20 hours after insemination, one to three grade A embryos were transferred at day 3 fertilization.

The luteal phase support was initiated from the day of oocyte retrieval for all patients with (Cyclogest 400 mg, Actavis pharmaceutical, UK) vaginal suppositories per day till the day of serum pregnancy test was done.

Serum β-hCG was performed 14 days after the embryo transfer to confirm chemical pregnancy. Clinical pregnancy was confirmed when there was an evidence of gestational sac, embryo and fetal heart activity at time of transvaginal ultrasound evaluation by the 6th week. ;

Study Design

Related Conditions & MeSH terms

Invitro Fertilization

Clinical Trial Details

NCT number	NCT03263299
Study type	Interventional
Source	Cairo University
Contact	Ahmed Maged, MD
Phone	01005227404
Email	prof.ahmedmaged@gmail.com
Status	Not yet recruiting
Phase	Phase 4
Start date	August 2017
Completion date	September 2018

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT03683043` - Comparative Study Between ICSI Results in Transvaginal Ultrasound Guided Embryo Transfer and Transabdominal Ultrasound Guided Embryo Transfer	Phase 4
Not yet recruiting	`NCT03684824` - Accuracy of Ultrasound Markers Versus Biochemical Markers in Prediction of Ovarian Response in Obese Women Undergoing IVF/ICSI Treatment	N/A
Recruiting	`NCT02329197` - Intrauterine Injection of Human Chorionic Gonadotropin Before Embryo Transfer in Women With Previous IVF Failure	Phase 4
Completed	`NCT02764255` - Embryoscope and Reproductive Outcome	N/A
Recruiting	`NCT02084940` - Long Acting GnRH Antagonist in PCOS Women Undergoing IVF	N/A
Completed	`NCT02674178` - FSH/LH Ratio as a Predictor of IVF Outcome in Young and Older Women	Phase 4
Completed	`NCT01576991` - Telomeres and Reproduction in Women	N/A
Recruiting	`NCT03457233` - The Impact of Body Weight on Reproductive Outcomes in Poor Ovarian Responders in ICSI Cycles	N/A
Completed	`NCT02660125` - Endometrial Injury and Implantation Rates Before First ICSI Cycle	N/A
Completed	`NCT03402620` - Poor Responders Infertile Patients -A Great Clinical Challenge	N/A
Completed	`NCT03831542` - Effect of Follicular Flushing in Patients With Mono-follicular Growth Undergoing In Vitro Fertilization
Completed	`NCT03118830` - Long Protocol and Freeze All Embryos vs Antagonist Protocol With Fresh Embryo Transfer in PCOS Patients Undergoing ICSI	Phase 4
Recruiting	`NCT02383394` - Factors Associated With Pregnancy Loss in IVF Women	N/A

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Value of Cabergoline and Low Dose Aspirin in Poor Responders Undergoing ICSI-ET With GnRH Agonist Flare-Up-Protocol

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms